Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study

BACKGROUND: Fruquintinib and regorafenib have been approved for the third-line therapy of metastatic colorectal cancer (mCRC) in China. However, at present, there is a lack of head-to-head clinical trials on the comparison of efficacy and safety between the two drugs. MATERIALS AND METHODS: The data...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Ya-Ya, Zhang, Xin-Yue, Zhu, Peng-Fei, Lu, Hong-Rui, Liu, Qian, Pan, Shuang-Yue, Chen, Zhe-Ling, Yang, Liu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020225/
https://www.ncbi.nlm.nih.gov/pubmed/36937443
http://dx.doi.org/10.3389/fonc.2023.1097911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020225/
https://www.ncbi.nlm.nih.gov/pubmed/36937443
http://dx.doi.org/10.3389/fonc.2023.1097911

Ejemplares similares